To study the potential mechanism of action of the m6A-associated genes in PAAD, the genetic mutation analysis shown in Figures 6(a) and 6(b) reveals that the mutation percentages of HNRNPC, IGF2BP2, IGF2BP3, KIAA1429, METTL3, METTL16, PCIF1, and YTHDF1 were 1.8%, 2.4%, 1.2%, 5%, 1.2%, 0, 0.6%, and 1.8%, respectively. The gene discussed is IGF2BP3; the disease is pancreatic adenocarcinoma.